Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:6/5/2008

CALGARY, June 5 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that that it has started patient enrolment in a Phase II clinical trial using intravenous administration of REOLYSIN(R) in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers. The principal investigator is Dr. Kevin Harrington of The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust.

This trial is a 14-patient, single arm, open-label, dose-targeted, non-randomized trial of REOLYSIN(R) given intravenously in combination with a standard dosage of paclitaxel and carboplatin. Eligible patients include those with advanced or metastatic head and neck cancers that are refractory to standard therapy or for which no curative standard therapy exists. The primary objective of the Phase II trial is to measure tumour responses and duration of response, and to describe any evidence of antitumour activity. The secondary objective is to determine the safety and tolerability of REOLYSIN(R) when administered in combination with paclitaxel and carboplatin to patients with advanced or metastatic head and neck cancer.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of Phase I/II and Phase II human trials using REOLYSIN(R), its proprietary formulation of the human reovirus, alone and in combination with radiation or chemotherapy. For further information about Oncolytics, please visit http://www.oncolyticsbiotech.com

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.K. Phase II combina
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015  Centrillion Technologies, a ... grant from the National Human Genome Research ... Health (NIH). The grant will help fund ... development of breakthrough genomic technologies, including phased ... substrates. Centrillion has been developing this transformative ...
(Date:4/17/2015)... April 17, 2015  US-Australian drug discovery company, Novogen, ... of Understanding with the Feinstein Institute for Medical ... to collaborate with the objective of ... The collaboration brings together the drug discovery expertise ... of the Feinstein Institute in neurosciences and oncology. ...
(Date:4/16/2015)... and OSAKA, Japan , ... Research Application (CiRA) of Kyoto University and Takeda ... will work together to develop clinical applications of ... heart failure, diabetes mellitus, neurological disorders and cancer ... Applications" (T-CiRA) is designed to expedite multiple research ...
(Date:4/16/2015)... CINCINNATI , April 16, 2015  Schulman Associates ... and technology, has signed a long-term lease on Laboratory ... Park, North Carolina . The location will house ... located to provide high quality reviews and customer service ... Raleigh represented Schulman in the deal, while ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Schulman IRB to Open Office in Research Triangle Park, N.C. 2
... Management Changes Announced, NEW YORK, March 5 ... announced that the company,s Board of Directors,has elected ... effective March 31, 2008. In this role, Mr. ... company,s fiscal operations, as,well as the global financial ...
... and computer engineering at the University of Delaware, ... Award from the National Science Foundation for his ... electronics known as spintronics. , This emerging field ... electrons to produce electronics ranging from computers to ...
... Investor Update Conference Call Set for March 7, ... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,it has entered into ... the privately-held specialty pharmaceuticals marketer which,Senetek licensed in ...
Cached Biology Technology:Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 2Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer 3UD's Appelbaum wins NSF Career Award for research on silicon spintronics 2UD's Appelbaum wins NSF Career Award for research on silicon spintronics 3Senetek PLC in Dispute With Marketer of Pyratine-6(TM) 2
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and ... addition of the "Global Iris Recognition Market 2015-2019" ... forecast the Global Iris Recognition market to grow at ... This report covers the present scenario and ... for the period 2015-2019. To calculate the market size, ...
(Date:3/24/2015)... BEACH GARDENS, Fla. , March 24, 2015 ... biometric identity management solutions, today announced that its ... premium clothing accessory retailer Goorin Bros . ... The Crossmatch biometrics-based solution secures access to the ... from the increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 ... fraud case conviction losses. This figure accounts for a ... according to The Nilson Report, exceeds $11 billion globally. ... tool after a crime has occurred. Investor Mark ... polygraph expert Joe Paolella partnered to administer ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... Amphibian populations are declining worldwide, and their declines far ... of all species are listed as threatened according to ... Conservation of Nature (IUCN). Multiple factors threaten global amphibian ... their interactions are poorly known. A new study published ...
... of ants, wasps and bees have long been a puzzle to ... queen and many workers come to be? A new model ... is divided into specialized castes that take on different roles within ... workers forego their own chance for reproduction and instead spend ...
... , , , , ... , AUDIO: Antibiotics ... one... , Click here for more information. ... , , , , , , ...
Cached Biology News:Predicting future threats for global amphibian biodiversity 2Communal living of the insect kind 2Probiotic protects intestine from radiation injury 2Probiotic protects intestine from radiation injury 3Probiotic protects intestine from radiation injury 4Probiotic protects intestine from radiation injury 5
Mouse monoclonal [SPM217] to Secretory Component Glycoprotein ( Abpromise for all tested applications)....
Glutamate Receptor 5/1a...
Dual Color Mouse anti-Human Anti-Kappa FITC/CD19 PE Class: Antibody Product Group: Immunogluobulin...
... Rabbit monoclonal [EP282Y] to ... for all tested applications). ... peptide corresponding to residues in ... synthetase. Entrez ...
Biology Products: